CTXR
NASDAQCitius Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.69+0.05 (+8.56%)
01:30 PM07:45 PM
News · 26 weeks34+75%
2025-11-022026-04-26
Mix2290d
- SEC Filings11(50%)
- Other9(41%)
- Offering2(9%)
Latest news
25 items- SECCitius Pharmaceuticals Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Oncology Ships First International Order of LYMPHIR™ to EuropeOrder fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional partners through Named Patient Programs in specific international marketsCRANFORD, N.J., April 29, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners, marking an important milestone in expanding access to the therapy for patients outside the United States. LYMPHIR will be made
- SECCitius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesCRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 5,076,143 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.985 per share (or pre-funded warrant in lieu thereof). In a concurrent private placement, the Company issued unregistered warrants to purchase up to 5,076,143 shares of common stock at an exe
- SECSEC Form 424B5 filed by Citius Pharmaceuticals Inc.424B5 - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesCRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 5,076,143 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.985 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,076,143 shares of comm
- SECCitius Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- SECCitius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma ExpertsCitius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings availableCRANFORD, N.J., March 24, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that members of its commercial and medical affairs teams will attend the USCLC Annual Workshop 2026. The meeting, titled "Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics, and Future Directions," will take place on March 26, 2026, at the Hyatt Regency Denver at Colorado Convention
- SECCitius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic CancersStudy data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacyTopline data of University of Pittsburgh-led trial to be presented at an upcoming international cancer conference later this yearCRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators. This study evalu
- SECCitius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell LymphomaTopline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was well-tolerated with no dose-limiting toxicities observedCRANFORD, N.J., March 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced positive topline safety and efficacy results from an investigator‑initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox‑cxdl) administered prior to co
- SECSEC Form DEFA14A filed by Citius Pharmaceuticals Inc.DEFA14A - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- SECSEC Form DEF 14A filed by Citius Pharmaceuticals Inc.DEF 14A - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development ProgramNon-dilutive capital supports continued execution and value creationCRANFORD, N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the Company has received $3.8 million in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program, funded through the New Jersey Economic Development Authority (NJEDA)."We are pleased to once again participate in New Jersey's NOL Program, which enables us to convert
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Citius Pharmaceuticals Inc.SCHEDULE 13G/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)
- SECCitius Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- SECSEC Form 10-Q filed by Citius Pharmaceuticals Inc.10-Q - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update. "The first quarter of fiscal 2026 marked a pivotal inflection point for Citius Oncology with the successful U.S. commerci
- PRCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (NASDAQ:CTOR). "I am thrilled to report that we have successfully transitioned to a revenue generating co
- PRCitius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with UnipharThird international distribution agreement further advances global access strategy with major markets in Europe CRANFORD, N.J., Feb. 11, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that it has entered into an exclusive distribution agreement with Uniphar ("Uniphar"), a leading international healthcare services company, to support access to LYMPHIR™ (denileukin diftitox-cxdl) outside the United States. This agreement represents Citius Oncology's third international distribution partnership and further advances the Company's strategy to expand glob
- SECAmendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc.10-K/A - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- SECCitius Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
- PRCitius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdateSubsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025. "2025 was a pivotal year for Citius as we successfully launched LYMPHIR following its FDA approval, marking the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) patients since 2018. This milestone reflects our ability to execute and our commitment t
CTXR FAQ
6 questionsWhat does Citius Pharmaceuticals Inc. do?
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries...Where does CTXR stock trade?
Citius Pharmaceuticals Inc. (CTXR) is listed on NASDAQ.What sector and industry is CTXR in?
Citius Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CTXR?
Citius Pharmaceuticals Inc. has had 3 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $900.00 price target on 2024-12-30. Recent price targets range from $400.00 to $900.00.What companies are similar to CTXR?
Notable peers in the same industry include RLMD (Relmada Therapeutics Inc.), MRNS (Marinus Pharmaceuticals Inc.), AMPE (Ampio Pharmaceuticals Inc.), TTNP (Titan Pharmaceuticals Inc.). Compare CTXR side-by-side with any of them on Quantisnow.How can I track CTXR on Quantisnow?
Quantisnow aggregates Citius Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTXR to receive live email and push alerts on every new disclosure.